Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.51 |
| ▸ | F9 | P00740 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | CD38 | P28907 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17802569 | 0.81 | MKNK1 (0.57) | MKNK1F9PRMT1CD38ROCK1 | |
| SCHEMBL17815595 | 0.81 | PRMT1 (0.69) | MKNK1F9PRMT1CD38CDC7 | |
| SCHEMBL17802611 | 0.80 | MKNK1 (0.56) | MKNK1F9PRMT1CD38ROCK1 | |
| SCHEMBL17802606 | 0.79 | MKNK1 (0.54) | MKNK1F9PRMT1CD38ROCK1 | |
| SCHEMBL17815689 | 0.78 | MKNK1 (0.51) | MKNK1F9PRMT1CD38ROCK1 | |
| SCHEMBL5569469 | 0.74 | KDR (0.72) | IRAK4KDREGFRFLT1 | |
| SCHEMBL17802597 | 0.74 | RAB9A (0.60) | KDREGFRMEN1KMT2ANPC1 | |
| SCHEMBL20680618 | 0.72 | CD38 (0.64) | CD38KDREGFR | |
| SCHEMBL17815579 | 0.71 | MKNK1 (0.52) | MKNK1F9PRMT1CD38ROCK1 | |
| SCHEMBL4103737 | 0.71 | F9 (0.52) | MKNK1F9CD38CDC7ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226861-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2017-10-11 | — | — | EP | claimed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | claimed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| EP-3226861-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | MKNK1 4044/4885F9 1061/4885PRMT1 1940/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | MKNK1 4044/4885F9 1061/4885PRMT1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.